Curis, Inc. (CRIS)

1.77
NASDAQ
Prev Close 1.77
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.60 / 3.33
Exchange NASDAQ
Shares Outstanding 33.15B
Market Cap 58.68M
Div & Yield N.A. (N.A)
Curis Regains Compliance With Nasdaq Continued Listing Requirements

Curis Regains Compliance With Nasdaq Continued Listing Requirements

LEXINGTON, Mass., April 10, 2019 /PRNewswire/ -- Curis, Inc.

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., April 5, 2019 /PRNewswire/ -- Curis, Inc.

Curis Reports Fourth Quarter And Year-End 2018 Financial Results

Curis Reports Fourth Quarter And Year-End 2018 Financial Results

-- Management to host conference call today at 4:30 p.m. ET --

Curis Sells Portion Of Erivedge Royalties To Oberland Capital For Up To $135.7 Million

Curis Sells Portion Of Erivedge Royalties To Oberland Capital For Up To $135.7 Million

- Curis received upfront payment of $65.0 million

Curis To Release Fourth Quarter And Year-End 2018 Financial Results And Host Conference Call On March 26, 2019

Curis To Release Fourth Quarter And Year-End 2018 Financial Results And Host Conference Call On March 26, 2019

LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Curis, Inc.

Curis Announces Presentation At Cowen & Company 39th Annual Healthcare Conference

Curis Announces Presentation At Cowen & Company 39th Annual Healthcare Conference

LEXINGTON, Mass., March 4, 2019 /PRNewswire/ --  Curis, Inc.

Curis, Inc. To Present At The 2019 BIO CEO & Investor Conference

Curis, Inc. To Present At The 2019 BIO CEO & Investor Conference

LEXINGTON, Mass., Feb.

First Mesothelioma Patient Dosed In CA-170 Study

First Mesothelioma Patient Dosed In CA-170 Study

LEXINGTON, Mass., Jan.

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., Jan.

Curis Reports Third Quarter 2018 Financial Results

Curis Reports Third Quarter 2018 Financial Results

-- New leadership increasing focus on clinical execution --

CRIS: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/30/2018 settlement date, and Curis Inc is one of the most shorted stocks of the Russell 3000, based on 7.52 "days to cover" versus the median component at 5.00. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Curis Reports Third Quarter 2017 Financial Results

Curis Reports Third Quarter 2017 Financial Results

-- Management to host conference call today at 8:30 a.m. EST --

Aurigene, A Wholly Owned Subsidiary Of Dr. Reddy's, And Curis Announce CA-170 Program Update Following Data Presented At ESMO 2017

Aurigene, A Wholly Owned Subsidiary Of Dr. Reddy's, And Curis Announce CA-170 Program Update Following Data Presented At ESMO 2017

Aurigene Discovery Technologies Limited, a wholly owned subsidiary of Dr.

Curis Reports Second Quarter 2017 Financial Results

Curis Reports Second Quarter 2017 Financial Results

-- Management to host conference call today at 8:30 a.m. EDT --

TheStreet Quant Rating: D- (Sell)